GSK to team up with Sino Biopharma for China launch of hepatitis B treatment
11/05/2026 07:26
May 11 (Reuters) - GSK GSK.L on Monday said it had entered into a strategic collaboration with Hong Kong-listed Sino Biopharmaceutical 1177.HK to accelerate the launch of its hepatitis B treatment bepirovirsen in mainland China. (Reporting by Prerna Bedi in Bengaluru) ((Prerna.Bedi@thomsonreuters.com; +91 98052 24616;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit